Eli Lilly is stepping further into oncology with an agreement to acquire closely held Ajax Therapeutics for up to $2.3 billion in cash, a ...

USA Rare Earth will buy a Brazilian mine to secure supply of heavy rare earths outside of Asia.

Britain resumes acceptance of Ajax armoured vehicles from General Dynamics after safety improvements, keeping within existing ...

Ajax deal expands Lilly’s oncology pipeline; Hematology focus adds depth beyond GLP therapies; Healthcare strategy gains ...

Eli Lilly (NYSE:LLY) agreed to acquire Ajax Therapeutics for up to $2.3b, adding a Type II JAK2 inhibitor program for ...

Lilly will pay up to $2.3B for Ajax and its AJ1‑11095 myelofibrosis drug; proof‑of‑concept data expected in 2026.

Eli Lilly (LLY) acquires Ajax Therapeutics for $2.3B, adding AJ1-11095, a novel JAK2 inhibitor for myelofibrosis and blood ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next ...

Earn these JavaScript certs to demonstrate mastery of the most in-demand skills for the world’s most-used programming ...

The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.